VOL. XCIV, NO. 247

* MOAT STOCKS COMPARISON *

NO ADVICE

Friday, December 26, 2025

Stock Comparison

Bristol-Myers Squibb Company vs Otis Worldwide Corporation

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Bristol-Myers Squibb Company

BMY · New York Stock Exchange

Market cap (USD)$110.3B
SectorHealthcare
CountryUS
Data as of2025-12-22
Moat score
56/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

View full moat analysis >

Otis Worldwide Corporation

OTIS · New York Stock Exchange

Market cap (USD)$62.7B
SectorIndustrials
CountryUS
Data as of2025-12-26
Moat score
67/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

View full moat analysis >

Side-by-side metrics

Bristol-Myers Squibb Company
Otis Worldwide Corporation
Ticker / Exchange
BMY - New York Stock Exchange
OTIS - New York Stock Exchange
Market cap (USD)
$110.3B
$62.7B
Sector
Healthcare
Industrials
HQ country
US
US
Primary segment
Eliquis franchise (apixaban)
Service
Market structure
Oligopoly
Competitive
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
56 / 100
67 / 100
Moat domains
Legal, Demand, Supply
Demand, Supply
Last update
2025-12-22
2025-12-26

Moat coverage

Shared moat types

No overlap yet.

Bristol-Myers Squibb Company strengths

IP Choke PointProcurement InertiaCapex Knowhow ScaleSwitching Costs General

Otis Worldwide Corporation strengths

Design In QualificationOperational ExcellenceBrand TrustInstalled Base ConsumablesService Field NetworkLong Term ContractsData Workflow Lockin

Segment mix

Bristol-Myers Squibb Company segments

Full profile >

Eliquis franchise (apixaban)

Oligopoly

27.6%

Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)

Oligopoly

26.4%

Hematology (Revlimid/Pomalyst/Reblozyl)

Competitive

23%

Immunology (Orencia/Sotyktu)

Competitive

8.1%

Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)

Competitive

14.9%

Otis Worldwide Corporation segments

Full profile >

New Equipment

Competitive

37.6%

Service

Competitive

62.4%

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.